Eli Lilly's third-quarter earnings fell short of Wall Street expectations, with revenue at $11.4 billion, missing forecasts of $12.1 billion. Sales of its obesity drugs, Mounjaro and Zepbound, reached $3.1 billion and $1.26 billion, respectively, but were lower than anticipated, leading to a significant drop in shares and a revised revenue guidance for the year. Despite these setbacks, company executives noted continued growth in underlying demand for their products.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.